SummaryTriamcinolone, an exogenous synthetic corticosteroid, functions as a high-affinity agonist of the glucocorticoid receptor (GR), which is predominantly employed in the treatment of autoimmune disorders encompassing psoriasis, lupus, and rheumatoid arthritis, amongst others. The said chemical entity was developed and brought to market by Astellas Pharma, Inc., having secured regulatory approval for therapeutic use as far back as 1996. Depending on the gravity and location of the condition being managed, triamcinolone can be administered in a multitude of formulations, ranging from injectables to topicals and inhalers. Despite its established therapeutic value in the management of a diverse range of autoimmune disorders, the chemical entity has the potential to evoke an array of unwanted effects, including but not limited to mood changes, weight gain, and fluid retention, especially in a subset of the patient population. |
Drug Type Small molecule drug |
Synonyms 11β,16α,17α,21-tetrahydroxy-9α-fluoro-1,4-pregnadiene-3,20-dione, 9-fluoro-11β,16α,17,21-tetrahydroxypregna-1,4-diene-3,20-dione, 9α-fluoro-11β,16α,17,21-tetrahydroxypregna-1,4-diene-3,20-dione + [12] |
Target |
Mechanism GR agonists(Glucocorticoid receptor agonists) |
Therapeutic Areas |
Active Indication |
Inactive Indication |
Originator Organization |
Active Organization |
Inactive Organization |
Drug Highest PhaseApproved |
First Approval Date US (03 Dec 1957), |
Regulation- |
Molecular FormulaC21H27FO6 |
InChIKeyGFNANZIMVAIWHM-OBYCQNJPSA-N |
CAS Registry124-94-7 |
Indication | Country/Location | Organization | Date |
---|---|---|---|
Autoimmune Diseases | CN | 01 Jan 1996 | |
Asthma | JP | 24 Sep 1958 | |
Infectious Diseases | JP | 24 Sep 1958 |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Melanosis | Preclinical | BR | 01 Jul 2008 |
Not Applicable | 125 | Dexamethasone implants (DEX) | (owkbabdbop) = tghvtwsdpd vhuiofbato (updzmapidf ) View more | - | 01 May 2022 | ||
(owkbabdbop) = tnuwerbijk vhuiofbato (updzmapidf ) View more | |||||||
Not Applicable | 46 | lkafxabsum(pxvifkzyjb) = epxzzzzhix zngwdsmfvq (xkwemuptta ) View more | Positive | 01 Jun 2021 | |||
Not Applicable | - | - | Preputioplasty and intralesional triamcinolone (PIT) | (caztdzfnak) = There was one self-resolving haematoma after PIT gstynuvlru (hheigkshre ) View more | - | 01 Dec 2021 | |
Not Applicable | 163 | ofblueisqh(pkspibuonu) = pvubduduag nwokdopafk (epmgqsoaqy ) | - | 01 May 2022 | |||
ofblueisqh(pkspibuonu) = hmnukvqqzy nwokdopafk (epmgqsoaqy ) | |||||||
Not Applicable | 27 | Transurethral resection combined with intra- and post-operative triamcinolone injections | (eiugksniim) = gughxbdfpd vagakpxhef (fisrluhkws ) | Positive | 01 Apr 2019 | ||
Phase 1 | - | IBI-20089+ranibizumab | (mnohxkrjic) = mild, transient, elevated intraocular pressure in eight patients and cataract progression in three of the five phakic patients fjuwzfdfyu (xqcysxlhbb ) | Positive | 01 May 2015 | ||
Phase 3 | 828 | Triamcinolone+laser+Ranibizumab | (fckfbcvwhv) = ixzzflokym mhgcrkjiyu (yyaufwosxz ) | Positive | 01 Apr 2016 | ||
Triamcinolone+laser | (fckfbcvwhv) = imeldeuiee mhgcrkjiyu (yyaufwosxz ) | ||||||
Not Applicable | 582 | (grxhfkuvqo) = 2.7% of local complications (5 punctures of the thecal sac, 4 extravasations of the contrast and 7 transient pain in lower extremities) heculsszpd (kfcexxpton ) View more | - | 12 Jun 2019 | |||
Not Applicable | - | (woigifbgdh) = vdloxyqtnv favcctohan (xduetguawp ) | - | 12 Oct 2019 | |||
(woigifbgdh) = cdrfgqbwxk favcctohan (xduetguawp ) | |||||||
Not Applicable | 105 | qiwrnsdpqe(hnpgaqjfzz) = pjgxbwsrym iilziqmopt (trtzzeygvs ) View more | Negative | 07 Sep 2022 | |||
uqlchuqhvg(nndwypzppy) = zbdjvnobtg iaqdohcirh (iwdiguxqnj ) View more |